Literature DB >> 26139553

Update on Medication-Overuse Headache and Its Treatment.

Maria Adele Giamberardino1, Dimos-Dimitrios Mitsikostas, Paolo Martelletti.   

Abstract

OPINION STATEMENT: Medication-overuse headache-i.e., a too-frequent consumption of acute headache medications leading to increased headache frequency and reduced effectiveness of acute and preventive treatments-is a serious medical condition whose pathophysiology still remains incompletely known, which is reflected into a lack of mechanism-based treatments. The first mandatory step in the therapeutic strategy remains withdrawal of the abused drug, preferably abrupt, in concomitance with a detoxification pharmacological regimen to lessen withdrawal symptoms. Intravenous hydration, antiemetics, corticosteroids (prednisone), tranquilizers (benzodiazepine), neuroleptics, and rescue medication (another analgesic than the overused) should be delivered in various combinations, on an inpatient (hospitalization and day hospital) basis or outpatient basis, depending on the characteristics of the specific patient and type of overuse. Inpatient withdrawal should be preferred in barbiturate and opioid overuse, in concomitant depression, or, in general, in patients who have difficulty in stopping the overused medication as outpatients. In contrast, in overuse limited to simple analgesics in highly motivated patients, without high levels of depression and/or anxiety, home detoxification should be chosen. Re-prophylaxis should immediately follow detoxification, ideally with local injections of onabotulinumtoxinA every 3 months or topiramate orally for at least 3 months. Adequate information to patients about the risks of a too-frequent consumption of symptomatic headache medications is essential and should constantly parallel treatment to help preventing relapse after detoxification and re-prophylaxis.

Entities:  

Year:  2015        PMID: 26139553     DOI: 10.1007/s11940-015-0368-z

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  57 in total

1.  OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial.

Authors:  S K Aurora; D W Dodick; C C Turkel; R E DeGryse; S D Silberstein; R B Lipton; H C Diener; M F Brin
Journal:  Cephalalgia       Date:  2010-03-17       Impact factor: 6.292

Review 2.  Definitions of medication-overuse headache in population-based studies and their implications on prevalence estimates: a systematic review.

Authors:  Maria L Westergaard; Ebba Holme Hansen; Charlotte Glümer; Jes Olesen; Rigmor H Jensen
Journal:  Cephalalgia       Date:  2013-11-29       Impact factor: 6.292

Review 3.  Practical management of medication-overuse headache.

Authors:  Koen Paemeleire; Luc Crevits; Peter J Goadsby; Holger Kaube
Journal:  Acta Neurol Belg       Date:  2006-06       Impact factor: 2.396

4.  Combined effect of common gene variants on response to drug withdrawal therapy in medication overuse headache.

Authors:  Sarah Cargnin; Michele Viana; Grazia Sances; Marika Bianchi; Natascia Ghiotto; Cristina Tassorelli; Giuseppe Nappi; Pier Luigi Canonico; Armando A Genazzani; Salvatore Terrazzino
Journal:  Eur J Clin Pharmacol       Date:  2014-08-07       Impact factor: 2.953

5.  Advice alone vs. structured detoxification programmes for medication overuse headache: a prospective, randomized, open-label trial in transformed migraine patients with low medical needs.

Authors:  P Rossi; C Di Lorenzo; J Faroni; F Cesarino; G Nappi
Journal:  Cephalalgia       Date:  2006-09       Impact factor: 6.292

6.  Frequencies of genetic polymorphisms related to triptans metabolism in chronic migraine.

Authors:  Giovanna Gentile; Serena Missori; Marina Borro; Alisa Sebastianelli; Maurizio Simmaco; Paolo Martelletti
Journal:  J Headache Pain       Date:  2010-03-06       Impact factor: 7.277

7.  The therapeutic armamentarium in migraine is quite elderly.

Authors:  Paolo Martelletti
Journal:  Expert Opin Drug Metab Toxicol       Date:  2014-12-01       Impact factor: 4.481

8.  Detoxification of medication-overuse headache by a multidisciplinary treatment programme is highly effective: a comparison of two consecutive treatment methods in an open-label design.

Authors:  Signe B Munksgaard; Lars Bendtsen; Rigmor H Jensen
Journal:  Cephalalgia       Date:  2012-06-29       Impact factor: 6.292

9.  Prednisone vs. placebo in withdrawal therapy following medication overuse headache.

Authors:  L Pageler; Z Katsarava; H C Diener; V Limmroth
Journal:  Cephalalgia       Date:  2007-11-26       Impact factor: 6.292

10.  Longterm prognosis of analgesic withdrawal in patients with drug-induced headaches.

Authors:  C Baumgartner; P Wessely; C Bingöl; J Maly; F Holzner
Journal:  Headache       Date:  1989-09       Impact factor: 5.887

View more
  7 in total

Review 1.  Medication Overuse in Chronic Pain.

Authors:  Eric S Hsu
Journal:  Curr Pain Headache Rep       Date:  2017-01

Review 2.  Anti-CGRP monoclonal antibodies in migraine: current perspectives.

Authors:  Maria Adele Giamberardino; Giannapia Affaitati; Martina Curto; Andrea Negro; Raffaele Costantini; Paolo Martelletti
Journal:  Intern Emerg Med       Date:  2016-06-23       Impact factor: 3.397

3.  Medication-Overuse Headache: Differences between Daily and Near-Daily Headache Patients.

Authors:  Abouch V Krymchantowski; Stewart J Tepper; Carla Jevoux; Marcelo M Valença
Journal:  Brain Sci       Date:  2016-08-15

4.  The journey from genetic predisposition to medication overuse headache to its acquisition as sequela of chronic migraine.

Authors:  Paolo Martelletti
Journal:  J Headache Pain       Date:  2018-01-10       Impact factor: 7.277

Review 5.  Botulinum neurotoxin type A for the treatment of pain: not just in migraine and trigeminal neuralgia.

Authors:  Giorgio Sandrini; Roberto De Icco; Cristina Tassorelli; Nicola Smania; Stefano Tamburin
Journal:  J Headache Pain       Date:  2017-03-21       Impact factor: 7.277

6.  The challenge of managing headache disorders in a tertiary referral neurology clinic in Rwanda.

Authors:  Celestin Kaputu-Kalala-Malu; Timothy D Walker; Olga Ntumba-Tshitenge; Eric M Mafuta; Pierrot L Tugirimana; Jean P Misson
Journal:  Neurosciences (Riyadh)       Date:  2016-04       Impact factor: 0.906

7.  OnabotulinumtoxinA: An Effective Tool in the Therapeutic Arsenal for Chronic Migraine With Medication Overuse.

Authors:  Edoardo Caronna; Victor José Gallardo; Natalia Hernández-Beltrán; Marta Torres-Ferrus; Patricia Pozo-Rosich
Journal:  Front Neurol       Date:  2018-10-16       Impact factor: 4.003

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.